Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic upper airway disease that may involve different inflammatory endotypes, although in Western populations it is most commonly associated with type 2 inflammation. CRSwNP has a significant impact on the patient’s quality of life. The recommended appropriate medical therapy is effective in controlling CRSwNP symptoms in many patients; however, a subset continues to exhibit persistent type 2 inflammation, evidenced by recurrent nasal polyps, elevated eosinophil counts, or the need for systemic corticosteroids or surgery. Monoclonal antibodies have recently become a novel and personalized treatment that can help refractory patients restore disease control. Objective: The present study aims to evaluate the effectiveness of mepolizumab in real-world settings in a diverse patient population, focusing on assessing the impact of this therapy on patient-reported outcomes after six months of treatment. Methods: This is a multicenter, observational study of CRSwNP patients treated with mepolizumab carried out in five hospitals located in Spain. Adult patients with a diagnosis of uncontrolled CRSwNP were included in the study. The change in the nasal polyp score (NPS) was the main clinical endpoint. Changes in the Sinonasal Outcome Test (SNOT-22), nasal congestion and smell impairment visual analogue scale scores, and blood and nasal polyp tissue eosinophil counts were among other endpoints included. Results: In total, 47 patients were included, and 91% were asthmatic. The nasal polyp score (0–8) was reduced significantly in the cohort (mean change: −2.56, p < 0.0001). The mean SNOT-22 score improved 25.29 points. Nasal congestion (−3.57, p < 0.0001) and smell impairment (−4.0, p < 0.0001) visual analog scale scores (0–10) showed a significant improvement. Blood and tissue eosinophil median counts showed significant reductions versus baseline of 86% and 26%, respectively. Among those patients with asthma, the asthma control test score achieved a median value of 24 points. Conclusions: This study provides real-world evidence supporting the effectiveness of mepolizumab in managing CRSwNP in patients with features suggestive of type 2 inflammation. The observed improvements in patient-reported outcomes, nasal polyp burden, and asthma control suggest that mepolizumab may be a valuable therapeutic option for this patient population.
9 December 2024 in European Annals of Otorhinolaryngology, Head and Neck Diseases
Purpose: Odontogenic sinusitis (ODS) is a frequent but underdiagnosed condition requiring multidisciplinary management. This study aims to compare outcomes between single-stage combined surgical treatment by otolaryngology and maxillofacial surgery teams versus non-combined approaches, and to evaluate whether the type of prior treatment influences the need for reintervention or secondary procedures. Methods: We conducted a retrospective observational study including 96 patients with ODS surgically treated between January 2019 and December 2024. Patients were categorized according to etiology and surgical strategy (combined vs. non-combined). Additionally, we analyzed whether the type of previous treatment (none, otolaryngology alone, maxillofacial surgery, dentist, or combined) was associated with the need for reoperation or second-stage maxillofacial surgery. Results: Combined surgery significantly reduced reoperation rates (p = 0.003), particularly in periodontic/endodontic infection cases (p = 0.002). No significant differences were observed in the need for second-stage maxillofacial surgery between groups. Reoperation was more frequent among patients initially treated by otolaryngology or maxillofacial surgeons, while those managed first by dentists had significantly lower reoperation rates (p < 0.001). The type of previous treatment was not significantly associated with second-stage maxillofacial surgery. Etiology and patient age did not influence surgical outcomes. Conclusion: Single-stage combined surgery reduces the need for reoperation in ODS. When a staged approach is selected, prioritizing initial dental or maxillofacial management before otolaryngologic intervention appears to yield better outcomes.
Background and Objectives: Graves’ orbitopathy (GO) is an autoimmune disease that can cause severe visual dysfunction and cosmetic impairment. Pure endoscopic orbital decompression reduces proptosis with minimal external morbidity. However, studies integrating both objective outcomes and patient-reported quality of life remain limited. This study aimed to analyze objective and subjective outcomes of pure endoscopic orbital decompression in inactive GO. Materials and Methods: We retrospectively reviewed 20 consecutive patients with severe inactive GO who underwent pure endoscopic transnasal orbital decompression between 2020 and 2023. Proptosis was measured using Hertel exophthalmometry, and quality of life was assessed with the disease-specific GO-QoL (Graves’ Ophthalmopathy Quality of Life) questionnaire (functional and appearance subscales). Minimum follow-up was 12 months. Pre- and postoperative changes were compared using paired t tests. Results: A total of 26 orbits were operated on. Mean proptosis decreased by 3.85 mm (p < 0.001). GO-QoL improved in the functional (+3.27, p < 0.001) and appearance (+5.77, p < 0.001) subscales. No complications or new/worsened diplopia were observed. Conclusions: Pure endoscopic orbital decompression is a safe and effective technique to reduce proptosis in inactive GO. Although quality-of-life scores improved significantly, the clinical relevance may vary, highlighting the need to integrate objective outcomes and patient perception when evaluating surgical results.
18 August 2026 in European Annals of Otorhinolaryngology, Head and Neck Diseases
Background: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a type-2 inflammatory upper respiratory disease that has a significant impact on the patient's quality of life. The recommended appropriate medical therapy is effective in controlling CRSwNP symptoms, but some patients are unable to control inflammation. Monoclonal antibodies have recently become a novel and personalized treatment that can help refractory patients restore disease control. Objective: The present study aims to evaluate the effectiveness of mepolizumab in real life settings in a diverse patient population, focusing on assessing the impact of this therapy on patient reported outcomes after six months of treatment. Methods: This is a multicenter, observational study of CRSwNP patients treated with mepolizumab carried out in five hospitals located in Spain. Adult patients with a diagnosis of uncontrolled CRSwNP were included in the study. The change in nasal polyp score (NPS) was the main clinical endpoint. Changes in Sinonasal Outcome Test (SNOT-22), nasal congestion and smell impairment visual analogical scales and blood and nasal polyp tissue eosinophil counts were among other endpoints included. Results: 47 patients were included. 91% were asthmatic. The nasal polyp score (0-8) was reduced significantly in the cohort (mean change: -2.56, p 0.0001). Mean SNOT-22 score improved 25.29 points. Nasal congestion (-3.57, p<0.0001) and smell impairment (-4.0, p<0.0001) visual analogical scales (0 -10) showed a significant improvement. Blood and tissue eosinophil median counts showed a significant reduction versus baseline of 86% and 26% respectively. Among those patients with asthma, the asthma control test score achieved a median value of 24 points. Conclusion: This study provides compelling evidence for the effectiveness of mepolizumab in managing recalcitrant CRSwNP in a real-world setting.